Finance

Lists
NOTA:FRA
ნოვარტისი
123,00 €
0,00%
(0,00) 1D
2 ოქტ, 22:00:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for NOTA...
Open
123,00 €
High
123,00 €
Low
123,00 €
Mkt. cap
289,09 მლრ.
Avg. vol.
27,00
Volume
0,00
52-wk high
145,00 €
52-wk low
102,50 €
No. of employees
75 ათ.
Open
123,00 €
High
123,00 €
Low
123,00 €
Mkt. cap
289,09 მლრ.
Avg. vol.
27,00
Volume
0,00
52-wk high
145,00 €
52-wk low
102,50 €
No. of employees
75 ათ.
News stories
From web sources and news partners
AD HOC NEWS
AD HOC NEWS
·
10 საათის წინ
Novartis stock fell 1.46 percent on October 2 after Abogen deal
AD HOC NEWS
AD HOC NEWS
·
1 დღის წინ
Novartis stock falls 1.46 percent after Abogen deal announcement
Euronext Markets: Real-time Stock Market Data | live
Euronext Markets: Real-time Stock Market Data | live
·
2 დღის წინ
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen
CNBC
CNBC
·
2 დღის წინ
Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About ნოვარტისი
CEOვასანტ ნარასიმჰანი
Employees75,3 ათ.
Founded7 მარ. 1996
Headquartersბაზელი, ბაზელ-შტადტის კანტონი, შვეიცარია
SectorPharmaceutical industry
Websitenovartis.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
14,36 მლრდ.
13,86 მლრდ.
13,52 მლრდ.
14,95 მლრდ.
Cost of goods sold
3,54 მლრდ.
3,54 მლრდ.
3,44 მლრდ.
3,68 მლრდ.
Cost of revenue
3,54 მლრდ.
3,54 მლრდ.
3,44 მლრდ.
3,68 მლრდ.
Research and development expenses
2,86 მლრდ.
2,84 მლრდ.
2,78 მლრდ.
2,74 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,30 მლრდ.
3,44 მლრდ.
3,14 მლრდ.
3,23 მლრდ.
Operating expense
6,24 მლრდ.
6,46 მლრდ.
5,96 მლრდ.
6,10 მლრდ.
Total operating expenses
9,77 მლრდ.
10,00 მლრდ.
9,40 მლრდ.
9,78 მლრდ.
Operating income
4,58 მლრდ.
3,86 მლრდ.
4,12 მლრდ.
5,18 მლრდ.
Other non operating income
-7,00 მლნ.
-130,00 მლნ.
4,00 მლნ.
19,00 მლნ.
EBT including unusual items
4,20 მლრდ.
3,22 მლრდ.
3,84 მლრდ.
4,27 მლრდ.
EBT excluding unusual items
4,29 მლრდ.
3,49 მლრდ.
3,78 მლრდ.
4,73 მლრდ.
Income tax expense
266,00 მლნ.
814,00 მლნ.
683,00 მლნ.
1,01 მლრდ.
Effective tax rate
6,34%
25,30%
17,79%
23,71%
Other operating expenses
70,00 მლნ.
190,00 მლნ.
42,00 მლნ.
127,00 მლნ.
Net income
3,93 მლრდ.
2,41 მლრდ.
3,16 მლრდ.
3,26 მლრდ.
Net profit margin
27,36%
17,38%
23,34%
21,83%
Earnings per share
2,25
2,03
1,99
2,41
Interest and investment income
-
373,00 მლნ.
-
-
Interest expense
-281,00 მლნ.
-304,00 მლნ.
-343,00 მლნ.
-462,00 მლნ.
Net interest expenses
-281,00 მლნ.
69,00 მლნ.
-343,00 მლნ.
-462,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
5,78 მლრდ.
4,96 მლრდ.
5,24 მლრდ.
6,30 მლრდ.
Gain or loss from assets sale
81,00 მლნ.
80,00 მლნ.
-159,00 მლნ.
-247,00 მლნ.
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები